{"id":251307,"date":"2024-01-24T00:00:00","date_gmt":"2024-01-24T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epibon0003-biopharma-ras-epidemiology-mature-markets\/"},"modified":"2026-03-31T10:31:08","modified_gmt":"2026-03-31T10:31:08","slug":"epibon0003-biopharma-ras-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epibon0003-biopharma-ras-epidemiology-mature-markets\/","title":{"rendered":"RAS &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of <abbr title=\"rat sarcoma\">RAS<\/abbr> comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of <abbr title=\"rat sarcoma\">RAS<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>The patient populations are forecast over a period of 20 years for the countries covered in this report. In addition to forecasting incident patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"rat sarcoma\">RAS<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people with <abbr title=\"rat sarcoma\">RAS<\/abbr>, how many in each of the major mature pharmaceutical markets have been formally diagnosed?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"rat sarcoma\">RAS<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 29 <abbr title=\"rat sarcoma\">RAS<\/abbr> patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases of <abbr title=\"rat sarcoma\">RAS<\/abbr>-mutated nonmetastatic cancer (all sites).<\/li>\n<li>Diagnosed incident cases of nonmetastatic <abbr title=\"rat sarcoma\">RAS<\/abbr>-mutated <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>.<\/li>\n<li>Diagnosed incident cases of metastatic <abbr title=\"rat sarcoma\">RAS<\/abbr>-mutated <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>.<\/li>\n<li>Diagnosed incident cases of recurrent metastatic <abbr title=\"rat sarcoma\">RAS<\/abbr>-mutated <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> adenocarcinoma.<\/li>\n<li>Diagnosed incident cases of metastatic <abbr title=\"rat sarcoma\">RAS<\/abbr>-mutated colorectal cancer.<\/li>\n<li>Diagnosed drug-treatable first-line <abbr title=\"rat sarcoma\">RAS<\/abbr>-mutated colorectal cancer population.<\/li>\n<li>Diagnosed incident cases of nonmetastatic <abbr title=\"rat sarcoma\">RAS<\/abbr>-mutated pancreatic exocrine tumor.<\/li>\n<li>\u2026 and many more (details available on request).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251307","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-oncology","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251307\/revisions"}],"predecessor-version":[{"id":281188,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251307\/revisions\/281188"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}